Lycia Therapeutics, Inc. LYCA

LYCA Company Overview

Lycia Therapeutics, Inc. is a privately held biotechnology company focused on developing targeted protein degradation therapies for diseases with high unmet medical need. The company operates within the biotechnology and pharmaceutical research sectors, with a primary emphasis on lysosomal targeting technologies designed to selectively degrade extracellular and membrane-bound proteins. Lycia’s core scientific platform centers on its proprietary lysosomal targeting chimera (LYTAC) technology, which aims to expand the scope of targeted protein degradation beyond intracellular proteins traditionally addressed by proteasomal degradation approaches.

The company was founded in 2019 and emerged from research originating at Stanford University, including work associated with the laboratory of Carolyn Bertozzi. Lycia has positioned itself within the emerging targeted protein degradation field by focusing on biologic and extracellular targets that are difficult to address using conventional small-molecule therapeutics. Its strategy emphasizes the development of therapeutics for oncology, immunology, and other serious diseases where selective protein removal may offer therapeutic advantages.